Clinical value of monitoring of plasma docetaxel concentration in patients with breast cancer in AC-T sequential chemotherapy

Abstract

Objective To investigate the relationship between plasma docetaxel concentration and the efficacy as well as toxic and side effects in patients with breast cancer after chemotherapy. Methods Seventy-one patients with breast cancer who accepted AC sequential T chemotherapy regimen as first line treatment were selected from April 2015 to September 2015 in Hubei Provicial Tumor Hospital.The plasma concentration of docetaxel was detected by latex immunoturdidimetry after the docetaxel continuous infusion in each cycle.The three groups were assigned according to the concentration distribution of docetaxel: group A (plasma concentration docetaxel ≤ 2.0mg·h-1·L-1), group B (2.1-2.5mg·h-1·L-1) and group C (≥2.6 mg·h-1·L-1). The relationship between the drug plasma concentration, therapeutic efficacy and adverse reactions in different docetaxel plasma concentration was analyzed retrospectively by Chi-square tests. Results The average plasma concentrations of docetaxel of the three groups were (1.55±0.36)mg·h-1·L-1, (2.28±0.13)mg·h-1·L-1, (2.87±0.38)mg·h-1·L-1 respectively.The adverse reactions were enhanced with the increasing of docetaxel plasma concentration (χ2=5.169, 4.463, 3.630, P=0.023, 0.035, 0.047). The therapeutic efficacy of group C and group B was same(95.8%), which was higher than 87.0% of group A, but there was no statistically significant difference(χ2=1.559, P=0.24). Conclusion Breast cancer patients whose plasma concentration of docetaxel is between 2.1~2.5mg·h-1·L-1 has a better prognosis, and its adverse reactions are controlled in a certain extent. Key words: Breast Neoplasms; Docetaxel; Drug Monitoring